Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G. Charrier N, et al. Among authors: hubbard j. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3664-8. doi: 10.1016/j.bmcl.2009.03.165. Epub 2009 Apr 17. Bioorg Med Chem Lett. 2009. PMID: 19428244
Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.
Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G. Charrier N, et al. Among authors: hubbard j. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3674-8. doi: 10.1016/j.bmcl.2009.03.149. Epub 2009 Apr 5. Bioorg Med Chem Lett. 2009. PMID: 19406640
Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.
Charrier N, Clarke B, Demont E, Dingwall C, Dunsdon R, Hawkins J, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G. Charrier N, et al. Among authors: hubbard j. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3669-73. doi: 10.1016/j.bmcl.2009.03.150. Epub 2009 Apr 5. Bioorg Med Chem Lett. 2009. PMID: 19477642
Racism in Drug Testing.
Hubbard JA, Johnson-Davis KL. Hubbard JA, et al. Clin Lab Med. 2024 Dec;44(4):607-617. doi: 10.1016/j.cll.2024.07.006. Epub 2024 Sep 20. Clin Lab Med. 2024. PMID: 39490119 Review.
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, Kasi A, Barzi A, Samuëlsz E, Karki A, Subramanian RA, Yemane D, Kim R, Wu CC, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Ahn DH, et al. Among authors: hubbard jm. J Clin Oncol. 2024 Oct 30:JCO2401266. doi: 10.1200/JCO-24-01266. Online ahead of print. J Clin Oncol. 2024. PMID: 39475591
Safety of Kidney Transplantation from Donors with HIV.
Durand CM, Massie A, Florman S, Liang T, Rana MM, Friedman-Moraco R, Gilbert A, Stock P, Mehta SA, Mehta S, Stosor V, Pereira MR, Morris MI, Hand J, Aslam S, Malinis M, Haidar G, Small CB, Santos CAQ, Schaenman J, Baddley J, Wojciechowski D, Blumberg EA, Ranganna K, Adebiyi O, Elias N, Castillo-Lugo JA, Giorgakis E, Apewokin S, Brown D, Ostrander D, Eby Y, Desai N, Naqvi F, Bagnasco S, Watson N, Brittain E, Odim J, Redd AD, Tobian AAR, Segev DL; HOPE in Action Investigators. Durand CM, et al. N Engl J Med. 2024 Oct 17;391(15):1390-1401. doi: 10.1056/NEJMoa2403733. N Engl J Med. 2024. PMID: 39413376
1,164 results